Precision Medicine in Low- and Middle-Income Countries

Annual Review of Pathology: Mechanisms of Disease - Tập 17 Số 1 - Trang 387-402 - 2022
Jerald P. Radich1,2,3, Edward L. Briercheck1,2, Daniel T. Chiu4, Manoj Menon1,2,3,5, Olga Sala‐Torra1, Cecilia C.S. Yeung1,3, Edus H. Warren1,2,3,5
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
2Global Oncology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA;
3School of Medicine, University of Washington, Seattle, WA 98195, USA
4Departments of Chemistry and Bioengineering, University of Washington, Seattle, WA 98195, USA
5Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

Tóm tắt

Most cancer cases occur in low- and middle-income countries (LMICs). The sophisticated technical and human infrastructure needed for optimal diagnosis, treatment, and monitoring of cancers is difficult enough in affluent countries; it is especially challenging in LMICs. In Western, educated, industrial, rich, democratic countries, there is a growing emphasis on and success with precision medicine, whereby targeted therapy is directed at cancers based on the specific genetic lesions in the cancer. Can such precision approaches be delivered in LMICs? We offer some examples of novel partnerships and creative solutions that suggest that precision medicine may be possible in LMICs given heavy doses of will, creativity, and persistence and a little luck.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(18)32252-9

WHO (World Health Organ.), 2019, Second WHO model list of essential in vitro diagnostics

10.1200/JCO.2015.61.9767

10.1038/bjc.2015.48

Cancer Fact Sheet 2020

WHO (World Health Organ.), 2017, Guide To Cancer Early Diagnosis

10.3389/fonc.2018.00346

10.1586/14737159.2013.835573

10.1056/NEJMoa030513

10.1182/blood-2006-01-0092

10.1182/blood-2012-10-462291

10.1182/blood-2013-02-483750

10.1038/sj.leu.2404318

10.1182/blood-2011-10-383000

10.1016/S1470-2045(10)70233-3

10.1182/hematology.2019000050

10.1182/blood-2015-12-689059

10.1373/clinchem.2007.085472

Qiagen, 2016, QIAamp® DNA mini and blood mini handbook

10.1200/JCO.2016.71.2083

10.3109/10428194.2013.827787

10.1182/bloodadvances.2021004347

10.1007/s12325-017-0612-x

10.1016/S0140-6736(18)32984-2

10.1002/ijc.29210

10.1038/sj.bjc.6604435

10.1016/S1470-2045(09)70335-3

10.1158/1055-9965.EPI-15-0535

10.1002/ijc.32406

10.1186/s13058-019-1174-4

Anderson BO, 2007, J. Natl. Compr. Cancer Netw., 5, 349

10.6004/jnccn.2014.0068

10.1002/cncr.23843

10.1002/cncr.23840

WHO Expert Comm. Sel. Use Essent. Med, 2014, The selection and use of essential medicines: report of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essential Medicines for Children)

10.1245/s10434-008-9900-7

10.1186/s12913-020-05752-y

10.1016/j.cll.2017.10.013

10.2471/BLT.16.187468

10.1309/1AKQDQ057PQT9AKX

10.1200/GO.20.00185

10.1097/PDM.0b013e3181e3630c

10.1056/NEJMoa0907847

10.2353/jmoldx.2007.060112

10.1038/s41374-018-0064-1

10.1007/s10549-018-4889-5

10.1038/nature11412

Ma CX, 2013, Oncology, 27, 1263

10.1056/NEJMoa1213261

10.1038/s41379-020-0601-5

10.1200/JGO.2015.002162

10.1016/j.cll.2017.10.001

10.1016/j.jaad.2010.05.032

Hashimoto Y, 2016, Yonago Acta Med, 59, 262

10.1086/650392

Sooknanan R, 1993, Exp. Hematol., 21, 1719

10.1016/j.jmoldx.2017.07.007

10.1038/nbt1385

10.1016/j.jmoldx.2015.01.007

10.1182/bloodadvances.2016000026

10.1182/blood-2018-05-851154

10.1007/978-1-4939-7778-9_3

10.1039/C8LC01223G

10.1039/C8LC00956B

10.1039/c2lc21247a

Thông tin
Thông tin xuất bản

Annual Review of Pathology: Mechanisms of Disease

Tập 17 Số 1

387-402

Thông tin tác giả